Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC FEINBERG

NPI
1255422127
CMS profile
329101
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$8,555.52

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC FEINBERG

NPI 1255422127 · CMS profile ID 329101

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255422127?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC FEINBERG, NPI 1255422127, CMS profile ID 329101. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255422127?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MARC FEINBERG, NPI 1255422127, CMS profile ID 329101. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255422127?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MARC FEINBERG, NPI 1255422127, CMS profile ID 329101, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1255422127?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $8,555.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
MDD US Operations, LLC $14.1606/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951616931 CMS
Janssen Pharmaceuticals, Inc $2.4406/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885904145 CMS
ACADIA Pharmaceuticals Inc $3,200.0006/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379125 CMS
ACADIA Pharmaceuticals Inc $62.1406/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379127 CMS
ACADIA Pharmaceuticals Inc $86.9806/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379129 CMS
ACADIA Pharmaceuticals Inc $35.0006/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379131 CMS
ACADIA Pharmaceuticals Inc $150.1606/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379133 CMS
ACADIA Pharmaceuticals Inc $34.4006/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379135 CMS
ACADIA Pharmaceuticals Inc $35.0006/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379137 CMS
ACADIA Pharmaceuticals Inc $20.3906/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379139 CMS
ACADIA Pharmaceuticals Inc $217.3706/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379141 CMS
ACADIA Pharmaceuticals Inc $524.6806/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379143 CMS
ACADIA Pharmaceuticals Inc $351.1906/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379145 CMS
ACADIA Pharmaceuticals Inc $41.4806/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379147 CMS
ACADIA Pharmaceuticals Inc $41.4806/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379149 CMS
ACADIA Pharmaceuticals Inc $20.7406/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379151 CMS
ABBVIE INC. $14.7506/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890949269 CMS
Lundbeck LLC $33.8806/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945747013 CMS
Genentech USA, Inc. $34.3306/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950769311 CMS
Novartis Pharmaceuticals Corporation $13.0506/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893627165 CMS
ARGENX US, INC. $400.0006/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951636805 CMS
Janssen Pharmaceuticals, Inc $19.6906/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885904133 CMS
Regeneron Pharmaceuticals, Inc. $820.0006/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927741351 CMS
Amgen Inc. $24.6305/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939436601 CMS
GENZYME CORPORATION $25.1405/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938819005 CMS
Janssen Pharmaceuticals, Inc $15.6905/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885904163 CMS
ACADIA Pharmaceuticals Inc $1.3505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952379123 CMS
MDD US Operations, LLC $19.0505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951616929 CMS
Lundbeck LLC $23.7204/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945747005 CMS
Lundbeck LLC $26.7304/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945747009 CMS
Horizon Therapeutics plc $19.1304/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937619495 CMS
Novartis Pharmaceuticals Corporation $12.6304/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893627161 CMS
BIOTRONIK INC. $57.2104/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949038109 CMS
BIOTRONIK INC. $27.7404/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949038103 CMS
BIOTRONIK INC. $45.5204/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949038105 CMS
BIOTRONIK INC. $144.5704/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949038107 CMS
BIOTRONIK INC. $316.6704/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949038113 CMS
BIOTRONIK INC. $316.6704/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949038111 CMS
Novartis Pharmaceuticals Corporation $14.5904/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893627157 CMS
Biohaven Pharmaceutical Holding Company Ltd. $14.7904/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923587267 CMS
Amgen Inc. $19.3604/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939436605 CMS
Janssen Pharmaceuticals, Inc $16.4404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885904174 CMS
Celgene Corporation $17.2804/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947211 CMS
Novartis Pharmaceuticals Corporation $13.6403/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893627153 CMS
AstraZeneca Pharmaceuticals LP $13.6303/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920230851 CMS
UCB, Inc. $26.6703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908001235 CMS
Teva Pharmaceuticals USA, Inc. $13.7603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954564575 CMS
Genentech USA, Inc. $21.8103/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950792113 CMS
GENZYME CORPORATION $21.2803/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938818979 CMS
Amgen Inc. $19.3603/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939436603 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,307.24 158
PY2020 $2,771.96 78
PY2021 $6,738.22 109
PY2022 $8,555.52 113
PY2023 $971.21 39
PY2024 $914.71 39
PY2025 $6,536.70 84

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $859.94 7
PY2025 Principal investigator $601,856.00 44
PY2024 Principal investigator $452,375.34 50
PY2023 Recipient $1,991.98 5
PY2023 Principal investigator $700,094.38 40
PY2022 Recipient $3,324.00 3
PY2022 Principal investigator $613,124.77 45
PY2021 Recipient $85,470.00 3
PY2021 Principal investigator $406,951.60 30
PY2020 Recipient $33,304.80 3
PY2020 Principal investigator $120,018.94 42
PY2019 Recipient $21,000.00 4
PY2019 Principal investigator $245,408.59 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 12/09/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187183
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 12/09/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187249
Principal investigator 1 ARGENX US, INC. $17,097.75 10/29/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237157334
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,499.38 10/27/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190308756
Principal investigator 1 GENZYME CORPORATION $11,152.00 10/20/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226084656
Principal investigator 1 ARGENX US, INC. $8,734.64 10/17/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237157325
Principal investigator 1 Janssen Research & Development, LLC $8,758.00 09/01/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187113
Principal investigator 1 ARGENX US, INC. $11,249.69 08/22/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237157321
Principal investigator 1 ARGENX US, INC. $1,800.00 08/15/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237157311
Principal investigator 1 ARGENX US, INC. $137.50 08/15/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237157318
Principal investigator 1 ARGENX US, INC. $5,500.00 08/01/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237157315
Principal investigator 1 ARGENX US, INC. $956.00 07/25/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237157304
Principal investigator 1 ARGENX US, INC. $1,700.00 07/23/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237157308
Principal investigator 1 Janssen Research & Development, LLC $8,270.00 07/15/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187265
Principal investigator 1 Eli Lilly and Company $382.00 07/10/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 1187890188
Principal investigator 1 ABBVIE INC. $3,577.97 06/24/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202492815
Principal investigator 1 Janssen Research & Development, LLC $7,592.00 06/17/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187281
Principal investigator 1 Eli Lilly and Company $764.61 06/09/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187890494
Principal investigator 1 Janssen Research & Development, LLC $6,616.00 05/28/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187228
Principal investigator 1 ARGENX US, INC. $10,050.00 05/21/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237157330
Principal investigator 1 ARGENX US, INC. $7,196.45 05/09/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237157301
Principal investigator 1 ABBVIE INC. $8,150.00 05/08/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202484559
Principal investigator 1 Janssen Research & Development, LLC $6,616.00 05/08/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187191
Recipient Merck Healthcare KGaA $607.94 04/25/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192507
Recipient Merck Healthcare KGaA $39.00 04/25/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192511
Recipient Merck Healthcare KGaA $30.00 04/25/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192515
Recipient Merck Healthcare KGaA $45.00 04/24/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192509
Recipient Merck Healthcare KGaA $30.00 04/24/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192513
Recipient Merck Healthcare KGaA $54.00 04/24/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192517
Recipient Merck Healthcare KGaA $54.00 04/23/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192519
Principal investigator 1 ABBVIE INC. $573.00 04/17/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202477788
Principal investigator 1 Eli Lilly and Company $4,194.00 04/08/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187889420
Principal investigator 1 GENZYME CORPORATION $2,709.00 04/07/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226084603
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,770.60 03/19/2025 Non-covered Recipient Entity
Sfm Clinical Research, Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235993717
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,750.00 03/19/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242338479
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,250.00 03/19/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242338481
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,500.00 03/19/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242338483
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 03/19/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242338485
Principal investigator 1 Janssen Research & Development, LLC $7,592.00 03/14/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187363
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $1,000.00 03/08/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, LONG-TERM, EXTENSION STUDY OF THE SAFETY AND EFFICACY OF AVP-786 (DEUTERATED [D6] DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335627
Principal investigator 1 Eli Lilly and Company $3,936.00 02/25/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187889406
Principal investigator 1 Eli Lilly and Company $846.44 02/25/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187890492
Principal investigator 1 Janssen Research & Development, LLC $8,270.00 02/20/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187218
Principal investigator 1 ARGENX US, INC. $5,900.76 01/30/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
A Phase 3b, Randomized, Open-Label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237157297
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,681.02 01/27/2025 Non-covered Recipient Entity
Sfm Clinical Research, Llc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235993721
Principal investigator 1 Janssen Research & Development, LLC $4,962.00 01/22/2025 Non-covered Recipient Entity
Sfm Clinic Research, Llc
Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1175187207
Principal investigator 1 ARGENX US, INC. $18,320.98 01/17/2025 Non-covered Recipient Entity
Sfm Clinical Research Llc
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237157328
Principal investigator 1 ABBVIE INC. $5,045.90 01/16/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202439803
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $357,136.10 01/16/2025 Non-covered Recipient Entity
Sfm Clinical Research, Llc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235993719
Principal investigator 1 ABBVIE INC. $6,042.19 01/03/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH LLC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202436552
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,646.02 01/01/2025 Non-covered Recipient Entity
SFM CLINICAL RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190308758